多模態成像市場：現況分析與預測（2023-2030）

Multimodal Imaging Market: Current Analysis and Forecast (2023-2030)

出版日期: 2023年08月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 158 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

由於製藥公司加大了對多模態成像先驅的投資，因此預計多模態成像市場在預測期內將以 5% 的複合年增長率強勁增長。製藥公司採用策略聯盟來維持在全球市場的競爭力。同樣，瑞士醫療軟體公司 SOPHiA GENETICS 與製藥公司阿斯特捷利康 (AstraZeneca) 合作，在癌症藥物開發中利用多模態成像技術。另外，生技公司也在努力尋找使用多模態影像診斷癌症的更好方法。例如，醫療技術巨頭西門子醫療將在2022年推出具有最少晶體元素的BiographVision，它將提供更高的空間分辨率，改變癌症診斷中病灶的可檢測性。醫療保健領域的大規模投資預計將使多模態成像市場的機會多樣化並呈指數級擴大。

依技術劃分，市場分為 PET/CT、SPECT/CT、PET/MR、OCT/眼底影像等。由於能夠檢測體內異常活動，PET/CT 在 2022 年佔據了最高的市場。 PET/CT 已被發現比其他診斷影像測試更靈敏、更準確。最近的發展已將人工智慧 (AI) 整合到 PET/CT 中，以提高影像品質並優化日常工作流程。同樣，聯影於 2023 年 7 月在核醫學和分子影像學會 (SNMMI) 上宣布推出具有下一代 PET/CT 系統和無縫 AI 的整合分子技術平台。因此，技術先進產品的快速推出正在推動該細分市場在預測期內的成長。

根據應用，市場分為腫瘤學、心臟科、神經學、骨科等。由於癌症患者的增加，2022年的市場份額由癌症領域主導。美國癌症協會估計，到 2023 年，美國將新增超過 190 萬癌症病例，約 60 萬人死於癌症。另外，這是由於尋找癌症永久治療方法的研究和開發工作不斷增加，以及由於其靶向性質而更多地採用診斷掃描儀對轉移性腫瘤細胞進行成像，這對該領域的增長產生了積極影響。例如，2023年2月，美國 FDA 核准 Gemperi 用於治療錯配修復缺陷（dMMR）、復發或晚期子宮內膜癌的成年患者。因此，癌症盛行率的增加正在推動癌症領域的發展。

依最終用戶劃分，市場分為醫院、診斷影像中心等。由於近年來政府支持力道加大，醫院類別在2022年佔據市場份額最高。例如，2021 年 8 月，韓國政府資助了由韓國國家研究基金會 (NRF) 領導的一個項目，研究利用多模態成像可視化骨轉移中腫瘤微環境的可行性。預計此類舉措將對細分市場的成長產生正面影響。因此，越來越多的政府措施正在推動醫院的發展。

為了更了解多模態影像產業的市場採用情況，將市場分為北美（美國、加拿大和北美其他地區）、歐洲（德國、英國、法國、西班牙、義大利和歐洲其他地區） ,亞太地區根據全球分佈（中國、日本、印度、亞太地區其他地區）和世界其他國家進行分析。 2022年的市場由北美主導。有幾個因素正在推動該區域市場的發展，包括醫療保健支出的增加、慢性病的快速增加、患者意識的提高、大多數主要參與者的存在以及隨之而來的研發活動的增加。例如，美國亞馬遜於 2023 年 8 月推出了一項符合 HIPAA 要求的新服務 AWS HealthImaging。它具有多模態分析功能，結合臨床影像、組學數據和健康記錄，為精準醫療提供醫學見解。因此，醫療保健投資的增加正在推動北美多模式成像的成長。

Multimodal imaging, also known as multiplexed imaging is the incorporation of multiple imaging techniques within a single setting. This technique helps in obtaining precise characterization of body parts by making accurate differential diagnoses. Multimodal imaging combines morphofunctional information by asynchronous or synchronous means. It can help in tracking cellular events and their progression in real time in rare diseases like familial esophageal neoplasia. These are utilized for the diagnosis and management of several chronic diseases, including cancer, heart diseases, neural diseases, and others. The main advantage of multimodal imaging is the earlier detection of disease and also in localizing the cells like malignant cells of cancer. The multimodal imaging market is growing at a tremendous rate owing to a surge in the prevalence of diseases like cancer, a rise in the geriatric population, increased expenditure in healthcare, advancements in healthcare technologies, and the popularity of personalized medicine.

The Multimodal Imaging Market is expected to grow at a strong CAGR of 5% during the forecast period owing to the rising pharmaceutical investment for the development of multimodal imaging. Pharmaceutical companies have adopted strategic alliances to maintain a competitive edge in the global market. Likewise, Switzerland-based medicine software company SOPHiA GENETICS collaborated with pharmaceutical company AstraZeneca to use multimodal imaging techniques for cancer drug development. Apart from this, biotechnology companies are also making efforts to find better diagnosis methods for cancer using multimodal imaging. For instance, Medtech giant Siemens Healthineers introduced a PET/CT system with a biograph vision with minimized crystal elements, delivering a higher spatial resolution that modifies lesion detectability in cancer diagnosis in the year 2022. These bulky investments in the healthcare sector are going to diversify and amplify the opportunities tremendously in the multimodal imaging market.

Based on technology, the market is segmented into PET/CT, SPECT/CT, PET/MR, OCT/fundus imaging, and others. The PET/CT held the highest share in the market in the year 2022 owing to its ability to find abnormal activities in the body. PET/CT is found to be more sensitive and accurate than other diagnostic imaging tests. Recent developments have integrated Artificial Intelligence (AI) with PET/CT which has optimized daily workflow along with providing improved quality images. Likewise, United Imaging has introduced Next-Generation PET/CT systems and an integrated molecular technology platform with seamless AI at The Society of Nuclear Medicine and Molecular Imaging (SNMMI) in July 2023. Thus, the rapid launch of technologically advanced products is driving the growth of the segment in the forecast period.

Based on application, the market is categorized into oncology, cardiology, neurology, orthopedics, and others. The oncology segment held the dominant share in the market in 2022 owing to the rise in the prevalence of cancer cases. The American Cancer Society estimated more than 1.9 million new cancer cases and approximately 0.6 million cancer deaths in the U.S. in the year 2023. Apart from this, rising research and development for finding a permanent cure for cancer and increasing adoption of diagnostic scanners for imaging metastatic tumor cells due to their targeted nature are also having a positive impact on the growth of the segment. For instance, in February 2023, the U.S. FDA granted approval to Jemperli for adult patients with mismatch repair-deficient (dMMR), and recurrent or advanced endometrial cancer. Thus, the rising prevalence of cancer is driving the growth of the oncology segment.

On the basis of end users, the market is segmented into hospitals, diagnostic imaging centers, and others. The hospital category held the highest share in the market in 2022 attributed to the rising government support in recent years. For instance, the Korean government funded a project on potential visualization of tumor microenvironment in bone metastasis using multimodal imaging in August 2021 led by the National Research Foundation of Korea (NRF). Such initiatives are expected to positively affect the segment growth. Thus, the rising government initiatives are driving the growth of the hospital.

For a better understanding of the market adoption of the multimodal imaging industry, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the market in 2022. Several factors such as increasing healthcare expenditure, the surge in the prevalence of chronic diseases, rising patient awareness, and the presence of the majority of key players and their associated surge in research and development activities are driving the regional market. For instance, in August 2023, U.S's Amazon launched its new HIPAA-eligible service- AWS HealthImaging which is equipped with a multimodal analysis feature that combines clinical imaging with omics data as well as health records to provide medical insights for precision medicine. Hence, the rising investments in healthcare are driving the growth of multimodal imaging in North America.

Some of the major players operating in the market include: Siemens; Bruker; GE Healthcare; Canon Inc.; Mediso Ltd.; MILabs B.V.; MR Solutions Ltd.; Koninklijke Philips N.V.; PerkinElmer, Inc.; Shanghai United Imaging Healthcare Co., Ltd.

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Multimodal Imaging Market
2.2. Research Methodology of the Multimodal Imaging Market
2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE MULTIMODAL IMAGING MARKET

6 MULTIMODAL IMAGING MARKET REVENUE (USD BN), 2022-2030F

7 MARKET INSIGHTS BY TECHNOLOGY

7.1. PET/CT
7.2. SPECT/CT
7.3. PET/MR
7.4. OCT/Fundus Imaging
7.5. Others

8 MARKET INSIGHTS BY APPLICATION

8.1. Oncology
8.2. Cardiology
8.3. Neurology
8.4. Orthopedics
8.5. Others

9 MARKET INSIGHTS BY END USER

9.1. Hospital
9.2. Diagnostic Imaging Centers
9.3. Others

10 MARKET INSIGHTS BY REGION

10.1. North America
- 10.1.1. U.S.
- 10.1.2. Canada
- 10.1.3. Rest of North America
10.2. Europe
- 10.2.1. Germany
- 10.2.2. U.K.
- 10.2.3. France
- 10.2.4. Italy
- 10.2.5. Spain
- 10.2.6. Rest of Europe
10.3. Asia-Pacific
- 10.3.1. China
- 10.3.2. Japan
- 10.3.3. India
- 10.3.4. Rest of Asia-Pacific
10.4. Rest of World